[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Neha Krishnamohan, Chief Financial Officer and Director of Artiva Biotherapeutics (ARTV), reported two withholding transactions tied to restricted stock unit vesting. On 05/15/2025 the issuer withheld 1,341 shares at a price of $2.13, leaving 108,659 shares beneficially owned. On 08/15/2025 the issuer withheld 5,813 shares at $2.75, leaving 102,846 shares beneficially owned.

The filing clarifies these were tax-withholding actions to satisfy income tax obligations associated with RSU vesting. The Form 4 was signed by Ms. Krishnamohan on 08/18/2025.

Positive

• Clear disclosure of withholding events and their purpose (tax obligations related to RSU vesting).
• Continued insider ownership above 100,000 shares after the transactions (102,846 shares).

Negative

• Reduction in beneficial ownership by 7,154 shares due to tax withholding.
• Withholdings executed at prices of $2.13 and $2.75, which marginally reduced the CFO's share count.

Insights

Financial Analyst

TL;DR: Routine tax-withholding transactions reduced the CFO's share count by 7,154 shares; no open-market sales reported.

The transactions reported are coded as withholding to satisfy tax obligations from RSU vesting rather than voluntary market sales, indicating no active divestment strategy disclosed. The reported prices ($2.13 and $2.75) reflect the withholding valuations on the respective vesting dates. Post-transaction ownership remains over 100,000 shares, preserving meaningful insider alignment with shareholders from a holdings-perspective. Impact on float or liquidity appears immaterial given the modest share numbers disclosed.

Corporate Governance Expert

TL;DR: Transactions are standard administrative with clear explanation; disclosure is timely and compliant.

The Form 4 identifies the reporting person, relationship to the issuer (CFO and Director), and provides an explicit explanation that shares were withheld to satisfy income-tax obligations from RSU vesting. The separate entries for May and August 2025 show appropriate reporting of each withholding event. There is no indication of additional derivative transactions or coordinated disposals in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krishnamohan Neha

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2025		F		1,341(1)	D	$2.13	108,659	D
Common Stock	08/15/2025		F		5,813(1)	D	$2.75	102,846	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Neha Krishnamohan	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Artiva (ARTV) Form 4 filed by Neha Krishnamohan report?

The filing reports two withholding transactions tied to RSU vesting: 1,341 shares withheld on 05/15/2025 at $2.13 and 5,813 shares withheld on 08/15/2025 at $2.75.

Why were shares withheld in the ARTV Form 4?

The filing states the shares were withheld by the issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

How many ARTV shares does the reporting person own after the transactions?

After the 05/15/2025 withholding the reporting person owned 108,659 shares, and after the 08/15/2025 withholding they owned 102,846 shares.

Was the Form 4 signed and when?

Yes, the Form 4 was signed by Neha Krishnamohan on 08/18/2025.

Do the transactions indicate open-market sales by the reporting person?

No. The transactions are coded as withholding (code F) and are described as issuer-withheld to satisfy taxes, not open-market sales.